chartexchange

Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update

PR Newswire | Nov 5, 2026 4:05 PM EST

Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into 2030...

Read original article